Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced that the US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), the company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. 13 June 2025
Related News
Insights
Company Spotlight
A private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
Latest News & Features of interest to Moderna
Pharmaceutical
US healthcare group Abbott has signed a wide-ranging agreement with health authorities in Abu Dhabi to localize pharmaceutical manufacturing, develop biosimilars, and accelerate digital transformation, as the emirate deepens its bid to become a regional powerhouse in the global life sciences sector. 20 June 2025
Biotechnology
Danish vaccine specialist Bavarian Nordic is set to collect $160 million from the sale of a US priority review voucher (PRV) earned through the approval of its chikungunya vaccine, Vimkunya (chikungunya vaccine), marking one of the highest prices paid for a PRV in recent years. 20 June 2025
Pharmaceutical
Privately-held UK firm Cycle Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Harliku (nitisinone) tablets for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU). 20 June 2025
Pharmaceutical
Japanese drugmaker Mochida Pharmaceutical announced that Thien Thao Pharmaceutical Joint Stock Company, a partner of Meiji, has obtained approval to import and market Epadel S, a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation sold by Mochida in Japan, for the treatment of hypertriglyceridemia in Vietnam. 20 June 2025
Pharmaceutical
A reshaped agenda for the Centers for Disease Control and Prevention’s vaccine advisory committee meeting on June 25–26 signals a departure from the initial vaccine slate. New appointees named by Health and Human Services Secretary Robert F. Kennedy Jr dismantled the previous committee structure two days after dismissing all 17 members. 20 June 2025
Biotechnology
Sanofi has signed a strategic agreement with health authorities in Abu Dhabi to accelerate vaccine development and manufacturing in the United Arab Emirates. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Biotechnology
SunRock Biopharma has teamed up with China’s Escugen to co-develop SRB123, a first-in-class antibody-drug conjugate (ADC) targeting CCR9, an antigen which is tied to particularly hard-to-treat cancers, including pancreatic, ovarian and lung. 18 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Pharmaceutical
US biopharma Mineralys Therapeutics has announced positive top-line data from its Phase II Explore-CKD trial evaluating the safety and efficacy of 25mg of lorundrostat in subjects with hypertension and comorbid chronic kidney disease (CKD). 18 June 2025
Latest In Brief for Moderna
Biotechnology
South Korea’s LigaChem Biosciences has signed two antibody licensing agreements with US biotech NovaRock Biotherapeutics, reports Korea Biomedical Review. 12 June 2025
Latest Relevant Ones To Watch News
US pharma major Eli Lilly (today announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading. 17 June 2025
12 June 2025
16 May 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze